返回 
加入收藏
复方谷氨酰胺肠溶胶囊防治恶性肿瘤患者放化疗相关肠道功能紊乱疗效的系统评价
x
请在关注微信后，向客服人员索取文件
| 篇名： | 复方谷氨酰胺肠溶胶囊防治恶性肿瘤患者放化疗相关肠道功能紊乱疗效的系统评价 |
| TITLE： | Compound glutamine enteric-coated capsules in the treatment and prevention of radiotherapy-and chemotherapy-related intestinal dysfunction in patients with malignant tumors：a systematic review |
| 摘要： | 目的 评价复方谷氨酰胺肠溶胶囊治疗和预防恶性肿瘤患者放化疗相关肠道功能紊乱的疗效。方法检索PubMed、Embase、中国知网、万方数据库，收集复方谷氨酰胺肠溶胶囊（试验组）联合或不联合其他治疗对比其他治疗或空白对照（对照组）的随机对照研究（RCT）及队列研究，检索时限为建库至2025年11月19日。经文献筛选、资料提取及质量评价后，采用RevMan5.4软件进行Meta分析。结果共纳入23项文献，共计2014例患者。Meta分析结果显示，试验组患者的治疗有效率显著高于对照组，总体、中重度放化疗相关肠道功能紊乱发生率和生活质量评分、白细胞介素6水平均显著低于对照组（P＜0.05）；两组患者的卡氏功能状态评分改善率、肿瘤坏死因子α水平比较，差异均无统计学意义（P＞0.05）。按对照组用药方案不同进行亚组分析的结果显示，治疗用药时，无论对照组患者使用空白对照还是阳性对照，试验组患者的治疗有效率均显著高于对照组（P＜0.05）；预防用药时，与对照组中使用空白对照的患者比较，试验组患者的总体及中重度放化疗相关肠道功能紊乱发生率均显著降低（P＜0.05），而试验组与对照组中使用阳性对照患者的总体及中重度放化疗相关肠道功能紊乱发生率比较，差异均无统计学意义（P＞0.05）。结论复方谷氨酰胺肠溶胶囊能有效治疗和预防恶性肿瘤患者放化疗相关肠道功能紊乱，改善患者生活质量，减轻炎症反应。 |
| ABSTRACT： | OBJECTIVE To evaluate the efficacy of Compound glutamine enteric-coated capsules in the treatment and prevention of radiotherapy- and chemotherapy-related intestinal dysfunction in patients with malignant tumors. METHODS PubMed， Embase， CNKI， and Wanfang data were searched to collect randomized controlled trial （RCT） and cohort studies comparing Compound glutamine enteric-coated capsules （experimental group） with or without other treatments versus other treatments or blank control （control group）. The search period was from the establishment of each database to November 19， 2025. After literature screening， data extraction， and quality assessment， a meta-analysis was performed using RevMan 5.4 software. RESULTS A total of 23 studies were included， involving 2 014 patients. Meta-analysis results showed that the effective rate in the experimental group was significantly higher than that in the control group， the overall incidence and moderate-to-severe incidence of radiotherapy- and chemotherapy-related intestinal dysfunction， quality of life scores， and interleukin-6 levels in the experimental group were significantly lower than those in the control group （ P ＜0.05）. However， no statistically significant differences were observed between the two groups in terms of Karnofsky Performance Status score improvement rate and tumor necrosis factor-α levels （ P ＞0.05）. The results of subgroup analysis based on different medications in the control group showed that， when used for treatment， regardless of whether patients in the control group received blank control or positive control， the efficacy in the experimental group was significantly higher than that in the control group （ P ＜0.05）. When used for prevention， compared with patients who received blank control in the control group， the overall incidence and the incidence of moderate-to-severe radiotherapy- and chemotherapy-related intestinal dysfunction in the experimental group were significantly reduced （ P ＜0.05）. No statistically significant difference was found in the overall incidence or incidences of moderate-to-severe radiotherapy- and chemotherapy-related intestinal dysfunction with positive control between the two groups （ P ＞0.05）. CONCLUSIONS Compound glutamine enteric-coated capsules can effectively treat and prevent radiotherapy- and chemotherapy-related intestinal dysfunction in patients with malignant tumors， improve patients’ quality of life， and alleviate inflammatory responses. |
| 期刊： | 2026年第37卷第08期 |
| 作者： | 陈俞先；邹丹；胡巧织 |
| AUTHORS： | CHEN Yuxian，ZOU Dan，HU Qiaozhi |
| 关键字： | 复方谷氨酰胺肠溶胶囊；肠道功能紊乱；恶性肿瘤；放疗；化疗；Meta分析；疗效 |
| KEYWORDS： | Compound glutamine enteric-coated capsules； |
| 阅读数： | 4 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
